缺血性心肌病心力衰竭阳虚水泛证与肠道菌群代谢产物的中西医研究进展

[2]FELKER G M, SHAW L K, O'CONNOR C M. A standardized definition of ischemic cardiomyopathy for use in clinical research [J]. J Am Coll Cardiol, 2002, 39(2): 210-218.

[3]RASMUSSEN M, PRADO A, HOMINAL M A, et al. Global Variations in Heart Failure Etiology, Management, and Outcomes [J]. JAMA, 2023, 329(19): 1650-1662.

[4]PASTENA P, FRYE J T, HO C, et al. Ischemic cardiomyopathy: epidemiology, pathophysiology, outcomes, and therapeutic options [J]. Heart Failure Reviews, 2024, 29(1): 287-299.

[5]KHAN M A, HASHIM M J, MUSTAFA H, et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study [J]. Cureus, 2020, 12(7): e9349.

[6]中国心血管健康与疾病报告编写组. 《中国心血管健康与疾病报告2022》要点解读 [J]. 中国心血管杂志, 2023, 28(4): 297-312.

[7]KNUUTI J, WIJNS W, SARASTE A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes [J]. Eur Heart J, 2020, 41(3): 407-477.

[8]王志军, 裴恒, 宿鑫, 等. 性别对新发心力衰竭的影响 [J]. 中国循环杂志, 2022, 37(1): 58-62.

[9]HAYASHI T, YAMASHITA T, WATANABE H, et al. Gut Microbiome and Plasma Microbiome-Related Metabolites in Patients With Decompensated and Compensated Heart Failure [J]. Circ J, 2018, 83(1): 182-192.

[10]张伯礼, 吴勉华. 中医内科学 [M]. 4版. 北京: 中国中医药出版社, 2017.

[11]毛静远, 朱明军. 慢性心力衰竭中医诊疗专家共识 [J]. 中医杂志, 2014, 55(14): 1258-1260.

[12]李欣源. 基于结构方程模型慢性心衰证素辨证量化研究 [D]. 广州: 广州中医药大学, 2021.

[13]马孝天, 陈瑞, 许朝霞, 等. 冠心病合并慢性心衰患者不同发展阶段中医证型的隐结构模型分析 [J]. 时珍国医国药, 2023, 34(8): 2012-2015.

[14]司锟. 慢性心力衰竭临床常见证型与心脏超声结果相关性研究 [J]. 中华中医药学刊, 2015, 33(6): 1505-1508.

[15]马静卓, 谭雨晴, 陈恒文. 中医药干预线粒体膜电位治疗心血管疾病的研究进展 [J]. 中国实验方剂学杂志, 2024, 30(12): 242-250.

[16]刘志强, 王海燕, 陈伟, 等. 慢性心力衰竭不同中医证型患者肠道菌群代谢产物差异分析 [J]. 中华中医药杂志, 2024, 39(5): 2456-2460.

[17]BRICENO N, SCHUSTER A, LUMLEY M, et al. Ischaemic cardiomyopathy: pathophysiology, assessment and the role of revascularisation [J]. Heart, 2016, 102(5): 397-406.

[18]STONE G W, SELKER H P, THIELE H, et al. Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials [J]. J Am Coll Cardiol, 2016, 67(14): 1674-1683.

[19]姚惠芳, 尹冬彩, 胡建强. 肥胖高血压糖尿病高血脂与冠心病的相关分析 [J]. 浙江中西医结合杂志, 2004, 14(1): 64-70.

[20]马依彤, 刘帅. 肥胖与心血管疾病的研究进展 [J]. 新疆医科大学学报, 2021, 44(10): 1111-1113.

[21]黄鹤, 刘建飞. 不同发病年龄冠心病病人临床特点及相关危险因素分析 [J]. 中西医结合心脑血管病杂志, 2019, 17(4): 636-638.

[22]ERQOU S, ADLER A I, CHALLA A A, et al. Insulin resistance and incident heart failure: a meta-analysis [J]. Eur J Heart Fail, 2022, 24(6): 1139-1141.

[23]JIN M, QIAN Z, YIN J, et al. The role of intestinal microbiota in cardiovascular disease [J]. J Cell Mol Med, 2019, 23(4): 2343-2350.

[24]KOREN O, SPOR A, FELIN J, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis [J]. Proc Natl Acad Sci U S A, 2011, 108(Suppl 1): 4592-4598.

[25]LUEDDE M, WINKLER T, HEINSEN F, et al. Heart failure is associated with depletion of core intestinal microbiota [J]. ESC Heart Fail, 2017, 4(3): 282-290.

[26]ROESSLER J, ZIMMERMANN F, HEIDECKER B, et al. Gut microbiota-related modulation of immune mechanisms in post-infarction remodelling and heart failure [J]. ESC Heart Fail, 2025, 12(2): 942-954. DOI: 10.1002/ehf2.15123

[27]HATAMNEJAD M R, MEDZIKOVIC L, DEHGHANITAFTI A, et al. Role of Gut Microbial Metabolites in Ischemic and Non-Ischemic Heart Failure [J]. Int J Mol Sci, 2025, 26(5): 2242. DOI: 10.3390/ijms26052242

[28]GUO S Y, et al. The bidirectional regulatory mechanism of gut microbiota metabolites on myocardial injury in heart failure from the perspective of the gut-heart axis: a review [J]. Front Microbiol, 2025, 16: 1710051. DOI: 10.3389/fmicb.2025.1710051

[29]YANG W, et al. Trimethylamine N-oxide and heart failure: from mechanisms to therapeutic potential [J]. Front Cardiovasc Med, 2024, 11: 1389215. DOI: 10.3389/fcvm.2024.1389215

[30]SHOKRAVI A, et al. Unraveling the choline pathway in heart failure risk and outcomes: A systematic review and meta-analysis [J]. Biochim Biophys Acta Mol Basis Dis, 2025, 1871(8): 168103. DOI: 10.1016/j.bbadis.2025.168103

[31]LI X, et al. Prognostic value of trimethylamine N-oxide in patients with coronary artery disease: a systematic review and meta-analysis [J]. Front Cardiovasc Med, 2023, 10: 1121216. DOI: 10.3389/fcvm.2023.1121216

[32]CHEN S, et al. Gut microbiota-derived metabolites in heart failure: mechanistic insights and therapeutic implications [J]. J Cardiovasc Transl Res, 2024, 17(3): 567-582. DOI: 10.1007/s12265-023-10478-1

[33]ZHU W, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk [J]. Cell, 2016, 165(1): 111-124.

[34]ROMANO K A, NEMET I, SAHA P P, et al. Gut Microbiota-Generated Phenylacetylglutamine and Heart Failure [J]. Circ Heart Fail, 2024, 17(4): e009972. DOI: 10.1161/CIRCHEARTFAILURE.123.009972

[35]WANG M, et al. Phenylacetylglutamine and cardiovascular outcomes in patients with chronic heart failure: a multicenter prospective study [J]. Eur J Heart Fail, 2025, 27(2): 312-321. DOI: 10.1002/ejhf.3512

[36]NEMET I, et al. A gut microbial metabolite of phenylalanine promotes heart failure by activating β-adrenergic receptors [J]. J Clin Invest, 2024, 134(8): e169234. DOI: 10.1172/JCI169234

[37]CHEN Y, et al. Gut microbial metabolite PAGln promotes ventricular arrhythmia via β-AR signaling [J]. Nat Cardiovasc Res, 2024, 3(5): 567-581. DOI: 10.1038/s44161-024-00456-2

[38]TANG W H W, et al. Gut microbiota and cardiovascular disease: from mechanisms to clinical translation [J]. Nat Rev Cardiol, 2024, 21(4): 235-250. DOI: 10.1038/s41569-023-00955-2

[39]ZHOU X, et al. Lipopolysaccharide and heart failure: a systematic review and meta-analysis [J]. Heart Fail Rev, 2024, 29(2): 345-358. DOI: 10.1007/s10741-023-10365-w

[40]MOLOUDIZARGARI M, et al. NLRP3 inflammasome in cardiovascular diseases: from mechanisms to therapeutic targeting [J]. J Mol Cell Cardiol, 2024, 187: 45-59. DOI: 10.1016/j.yjmcc.2024.01.002

[41]BROWN J M, et al. Gut microbiota-derived metabolites and mitochondrial dysfunction in heart failure [J]. Circ Res, 2024, 134(8): 1023-1040. DOI: 10.1161/CIRCRESAHA.123.323456

[42]ZHAO P, ZHAO S, TIAN J, et al. Significance of Gut Microbiota and Short-Chain Fatty Acids in Heart Failure [J]. Nutrients, 2022, 14(18): 3758. DOI: 10.3390/nu14183758

[43]HE X J, WANG Q, LONG Q, et al. The single-cell atlas of short-chain fatty acid receptors in human and mice hearts [J]. Front Immunol, 2025, 16: 1538384. DOI: 10.3389/fimmu.2025.1538384

[44]CHEN A T, ZHANG J, ZHANG Y. Gut microbiota in heart failure and related interventions [J]. iMeta, 2023, 2(3): e125. DOI: 10.1002/imt2.125

[45]AMJAD A, AZAM A, SHAH W, et al. Microbial metabolites in cardioprotection: an immune-engineered framework for heart failure and post-ischemic remodeling: a narrative review [J]. Ann Med Surg, 2026, 88(2): 1511-1520. DOI: 10.1097/MS9.0000000000004529

[46]SINHA S R, HAILESELASSIE Y, NGUYEN L P, et al. Dysbiosis-Induced Secondary Bile Acid Deficiency Promotes Intestinal Inflammation [J]. Cell Host Microbe, 2020, 27(4): 659-670. DOI: 10.1016/j.chom.2020.01.021

[47]CHEN F Y, GONG L H. Bile acid--microbiota interactions in cardiometabolic diseases: mechanisms and emerging therapeutic approaches [J]. Front Microbiol, 2025, 16: 1689026. DOI: 10.3389/fmicb.2025.1689026

[48]吕超, 汪志新, 孟宪亮. 肠道菌群及其代谢物对心力衰竭的影响及中医干预研究进展 [J]. 光明中医, 2023, 38(15): 2943-2946.

[49]蓝宇, 罗富锟, 于悦, 等. 心力衰竭的中医认识与经方治疗策略 [J]. 中国中药杂志, 2024, 49(23): 6521-6532. DOI: 10.19540/j.cnki.cjcmm.20240816.501

[50]王科军, 张秀荣, 苏德成. 古代医家对慢性心衰病因病机的认识 [J]. 吉林中医药, 2011, 31(8): 711-712.

[51]葛鸿庆, 赵郝亮, 李敏. 邓铁涛教授从脾论治慢性充血性心力衰竭之经验 [J]. 上海中医药杂志, 2002, 36(4): 9-10.

[52]邹旭, 潘光明, 林晓忠. 以心脾相关理论试论心力衰竭的辨治 [J]. 广州中医药大学学报, 2007, 24(5): 419-421.

[53]张志敏, 杨硕. 气虚血瘀型慢性心力衰竭病因病机及治疗的研究进展 [J]. 实用中医内科杂志, 2024, 38(6): 56-58.

[54]SCISCIOLA L, et al. Dietary Nutrients, Gut Microbiota, and Cardiac Function: From Metabolic Mechanisms to Clinical Applications [J]. Nutrients, 2026, 18(3): 467. DOI: 10.3390/nu18030467

[55]张曦宁, 董振华, 赵震宇, 等. 真武汤对阿霉素诱导的慢性心力衰竭大鼠肠黏膜细菌多样性的影响 [J]. 湖南中医药大学学报, 2023, 43(8): 1368-1378. DOI: 10.3969/j.issn.1674-070X.2023.08.008

[56]王琪, 彭筱平, 潘沐勇. 失笑散合五苓散治疗阳虚水泛兼血瘀型慢性心衰临床观察 [J]. 山西中医, 2021, 37(5): 28-30.

[57]孙梓宜, 姚魁武, 王子涵, 等. 升解通瘀汤对缺血性心肌病致慢性心力衰竭气虚血瘀证患者尿液代谢组学的影响 [J]. 中医杂志, 2023, 64(7): 692-701. DOI: 10.13288/j.11-2166/r.2023.07.009

[58]AZAD M A K, SARKAR M, LI T, et al. Probiotic Species in the Modulation of Gut Microbiota: An Overview [J]. Biomed Res Int, 2018, 2018: 9478630. DOI: 10.1155/2018/9478630.

[59]BARILLA F, GAGLIARDI G, CAPANO F, et al. Gut microbiota composition and cardiovascular disease: potential new therapeutic target [J]. Int J Mol Sci, 2021, 22(19): 10288. DOI: 10.3390/ijms221910288.

版权与开放获取声明

作为一本开放获取的学术期刊，所有文章均遵循 Creative Commons Attribution 4.0 International License (CC BY 4.0) 协议发布，允许用户在署名原作者的前提下自由共享与再利用内容。所有文章均可免费供读者和机构阅读、下载、引用与传播，EWA Publishing 不会通过期刊的出版发行向读者或机构收取任何费用。